Dr. Chandrasekhar Padmanabhan, MD

Dr. Padmanabhan practices at Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center.

Dr. Padmanabhan's NPI, 1699066068, was assigned on April 20, 2011. Dr. Padmanabhan holds Tennessee license 51909.

Dr. Padmanabhan's primary practice is Vanderbilt University Medical Center, at 1211 Medical Center Drive, Nashville, TN 37232 in Davidson County. The practice phone is (615) 322-3454.

Dr. Padmanabhan's primary practice is Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center. Dr. Padmanabhan is also affiliated with Vanderbilt Wilson County Hospital. The medical group on file is Vanderbilt University Medical Center. Dmand AI also links Dr. Padmanabhan to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Padmanabhan practices, 3 sites in all. Vendor and product names are available with a free account.

Surgical oncology is Dr. Padmanabhan's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Padmanabhan is licensed in Tennessee.

CMS data shows 121 Medicare services from Dr. Padmanabhan across 4 procedure codes in 2024, for 108 Medicare patients. Medicare paid $11,569 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 108 Medicare patients who saw Dr. Padmanabhan in 2024. The largest group is 65 to 74, with 60 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 12% are also on Medicaid. Their average risk score is 1.96, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Padmanabhan's median patient age at 68, with 42% women.

In 2024, Dr. Padmanabhan wrote 73 Medicare Part D claims for 23 patients. 42% of them were for generic drugs. CMS names the drug for 51 of them, across 2 drugs with 11 or more claims each, at $145,167 in total drug cost. In 2023, CMS named 29 claims across 1 drug.

Dr. Padmanabhan accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Padmanabhan as offering telehealth.

Dmand AI links 17 papers to Dr. Padmanabhan, published from 2014 to 2025. 2017 was the busiest year, with 5. The most frequent topics are Colorectal Neoplasms, Carcinogenesis and Cell Line, Tumor. Dr. Padmanabhan has published most often in Oncotarget. Dr. Padmanabhan's most frequent co-authors are Kamran Idrees, MD, Dai H. Chung, MD and Rajiv Agarwal.

CMS Open Payments shows 39 general payments to Dr. Padmanabhan from 4 drug and device companies from 2022 to 2025. Consulting fees make up the largest share, 66% of the total. Intera Oncology, Inc paid the most, $19,762.